KU Leuven Spin-off Hemastatx Develops First Therapy Targeting Root Cause of Severe Bleeding Disorder
Hemastatx, a new KU Leuven spin-off, has developed the first therapy to address the underlying mechanism of von Willebrand factor defects, a severe bleeding disorder affecting 100,000 hospitalized patients annually worldwide.
KU Leuven Researchers Develop Dual-Agent Method to Permanently Silence HIV Virus
Researchers at KU Leuven have developed a novel dual-agent approach that renders HIV permanently harmless by forcing the virus into a deep dormant state.
eXmoor Pharma and KU Leuven Form Strategic Alliance to Accelerate AAV Gene Therapy Development
eXmoor Pharma and KU Leuven have established a strategic partnership to support a new cell and gene therapy hub, focusing on accelerating AAV gene therapies from bench to first-in-human trials.
KU Leuven and UZ Leuven Launch €14 Million Advanced Therapy Production Facility
KU Leuven and UZ Leuven are investing €14 million to establish an Advanced Therapy Medicinal Products (ATMP) facility on the Gasthuisberg campus, scheduled to be operational by late 2025.